Core Insights - VolitionRx Limited has signed a co-marketing agreement with Hologic Diagenode to promote its Nu.Q Discover service, which focuses on epigenetic profiling for drug developers and scientists [1][3][4] Company Overview - VolitionRx is a multi-national epigenetics company dedicated to advancing the science of epigenetics, aiming to improve outcomes for patients through earlier detection and monitoring of diseases [12][13] - Hologic, a company with over $4 billion in revenue for 2024, specializes in medical technologies and has extensive experience in various disease areas, including oncology and immunology [5][10] Product and Market Potential - The Nu.Q Discover service offers state-of-the-art assays for rapid epigenetic profiling, with an estimated total addressable market of $200 million annually [4][7] - The partnership aims to expand customer access to Nu.Q Discover assays, potentially leading to Hologic becoming an exclusive provider of these services [3][4] Strategic Goals - The collaboration is expected to enhance the reach of Nu.Q Discover services, leveraging Hologic's established client base and international presence [5][6] - Both companies aim to create value for clients by identifying specific epigenetic signatures that can inform personalized medicine approaches [6]